

The Daily

December 07, 2023





DOMESTIC INDICES

	CLOSE	POINTS	% CHANGE
SENSEX	69654	358	0.52
NIFTY	20938	83	0.40
MIDCAP	35116	67	0.19
SMALL CAP	41174	75	0.18

SECTORAL INDICES

	CLOSE	POINTS	% CHANGE
POWER	5593	132	2.41
OIL & GAS	22246	429	1.96
IT	33711	486	1.46
CG	53120	654	1.25
TECK	15073	175	1.18
METAL	24856	116	0.47
AUTO	40582	30	0.07
FINANCE	10220	-5	-0.04
CD	47964	-30	-0.06
REALTY	5804	-8	-0.13
BANKEX	52911	-267	-0.50
HEALTHCARE	30354	-196	-0.64

BSE 200 GAINERS/LOSERS

GAINERS	%	LOSERS	%
ATGL	19.98	GICRE	-4.42
ADANIGREEN	16.11	CGPOWER	-4.13
ADANIENSOL	7.36	MAXHEALTH	-3.87
HAL	6.44	PAYTM	-3.12
SOLARINDS	6.10	DELHIVERY	-2.67

ADVANCE/DECLINES

	BSE	%
ADVANCES	1930	50
DECLINES	1824	47
UNCHANGED	141	4

INSTITUTIONAL ACTIVITY

Rs Cr	05-12-2023	06-12-2023	DEC TOTAL
FII	5224	-80	8807
DII	-1399	1372	6218

Indian markets could open flat to mildly lower, in line with mostly lower Asian markets today and negative US markets on Dec 06.

U.S. stocks finished lower on Wednesday after erasing earlier gains as investors awaited further labor-market data this week following weaker-than-expected November private-sector job figures.

U.S. businesses added 103,000 new jobs in November, paycheck company ADP said, in another sign of slower hiring and a softer U.S. labor market. That was below the 128,000 consensus forecast from economists polled by The Wall Street Journal. On Friday, the U.S. is expected to report 190,000 jobs added in November after a 150,000 increase in the prior month, according to economists.

The yield on the 10-year Treasury fell to a more-than-three-month low of 4.12% on Wednesday, extending the decline seen in the prior session.

The U.S. trade deficit widened in October to a three-month high of \$64.3 billion due to a decline in exports, according to government data published Wednesday. Meanwhile, imports inched up 0.2% in October to \$323 billion, mostly because of higher demand for computers and equipment to drill for oil.

The productivity of American workers rose by a revised 5.2% annual rate in the third quarter, the government said Wednesday. It is the fastest pace since the third quarter of 2020. Excluding the pandemic era, it's the fastest since the fourth quarter of 2009.

The Bank of Canada on Wednesday held its key overnight rate at 5% and left the door open to another hike, saying it was still concerned about inflation while acknowledging an economic slowdown and a general easing of prices.

Equities in Asia mirrored weakness on Wall Street. Investors braced for the fallout from Moody's Investors Service cutting its outlook for eight Chinese banks to negative from stable, a day after unveiling a bearish stance on the nation's sovereign bonds due to concern over the level of debt. A sharp fall in oil prices to a five-month low promised to further reduce inflationary pressures and helped boost the global bond market.



GLOBAL INDICES			
	CLOSE	POINTS	% CHANGE
DOW JONES	36054	-70.13	-0.19
S & P 500	4549	-17.84	-0.39
NASDAQ	15788	-89.66	-0.56
FTSE	7515	25.54	0.34
CAC	7436	49.00	0.66
DAX	16656	123.33	0.75
NIKKEI	32839	-607.40	-1.82
SHANGHAI	2961	-8.03	-0.27
HANG SENG	16212	-262.00	-1.59
BOVESPA	125623	-1281.00	-1.01

EXCHANGE RATES		
	VALUE	% CHANGE
USD/INR	83.4	0.20
EURO/USD	1.077	0.06
USD/GBP	1.256	-0.01
USD/JPY	146.8	-0.34

COMMODITIES		
	VALUE	% CHANGE
GOLD (\$ / Oz)	2045.4	-0.12
SILVER (\$ / Oz)	24.2	-0.30
CRUDE OIL FUTURES	69.7	0.52
BRENT OIL (\$ / Barrel)	74.6	0.43

BOND YIELD		
	VALUE	ABS CHANGE
IND10 YEAR BOND YIELD	7.248	-0.014

ADR		
	VALUE	% CHANGE
DR REDDY'S LAB	69.4	-0.46
HDFC BANK	62.7	-0.24
ICICI BANK	24.0	-1.52
TATA MOTORS	25.1	0.00
WIPRO	4.97	3.54
VEDANTA LTD	16.50	0.00
INFOSYS	17.69	1.32

Nifty ended at a record high rising for the seventh consecutive session on Dec 06. At close, Nifty was up 0.40% or 82.6 points at 20937.7. Nifty rose again on Dec 06 but formed a dragonfly doji like pattern which hints at top reversal. Although Nifty crossed 20915, the movement in the indices remained subdued later. Nifty could now remain in the 21,000- 20852 band for the near term. Dec 07 is the 8th day of rise which is a Fibonacci number and normally suggests a change of trend.

Auto retail sales grow by 18% in Nov; 2-wheeler, passenger vehicles reach all-time high

The Federation of Automobiles Dealers Associations (FADA) on Wednesday said that the auto sales in November grew by 18 per cent annually with a historic sale of 28.54 vehicles, surpassing March 2020 record of 25.69 vehicles. The apex body also said that the record sales come amid the industry's transition to BS-6 from BS-4 emission norms. Further, the 2-wheelers segment and passenger vehicles (PV) reached an all-time high with 22.47 lakh and 3.6 lakh vehicles sold respectively.

Government to divest 8% equity in IRCON via OFS

The offer for sale (OFS) for up to an 8% government stake in the railway public sector undertaking IRCON will open on Thursday. The floor price for the IRCON OFS would be ₹154 per equity share, the rail PSU said in a regulatory filing. The floor price of ₹154 is at a discount of over 10% from Wednesday's closing price. The government currently holds a 73.18% stake in IRCON, which is under the Railways Ministry and in the construction of transportation infrastructure. The base issue size of the OFS is 4%, or over 3,76,20,629 equity shares, with a green-shoe option to retain an over-subscription of 4%, or 3,76,20,629 shares. The total issue size, including the green-shoe option, comes to 8%, or over 7,52,41,258 shares.

BEL receives orders worth Rs. 3,915 Crore

Bharat Electronics Limited received an order of Rs 580 Crore from Indian Army for AMC of Radars. This project will have participation of Indian electronics and associated industries, including MSMEs, which are sub-vendors of BEL. The Company has also received additional orders worth Rs 3,335 Crore since the last disclosure on 15th Sept 2023 and the said orders pertain to AMC for AEW&C system (Airborne Early Warning & control), Uncooled TI sights, Software Defined Radios, SWIR pay load, AMC for IACCS, Passive Night Vision Binoculars etc.



Brigade Group signs JDA for Grade A Office Space in Bengaluru's CBD with Development Value of ₹500 Crores"

Brigade Group, has entered into a Joint Development Agreement (JDA) to develop a premium 'Grade A' office space on Sankey Road in Bengaluru's Central Business District. With a developable area of around 0.20 million square feet, the project has a Gross Development Value of around ₹500 crores.

Reliance-owned TV18 Broadcast to merge with Network18

Reliance-owned TV18 Broadcast Limited (TV18) announced a scheme of arrangement in terms of which TV18 and e-Eighteen.com Limited ("E18", which owns and operates MoneyControl website and app) will merge with Network18. The proposed scheme will consolidate TV and digital news businesses of the Network18 group in one company.

Brigade Group signs Ibis Styles Mysuru with Accor Group

Brigade Hotel Ventures Ltd. (BHVL), a wholly owned subsidiary of Brigade Enterprises Ltd. announces the signing of the first ibis Styles in Mysuru, the cultural capital of Karnataka. Nestled in a prime location, this vibrant addition to Brigade Group's portfolio, is set to redefine hospitality with its playful design, contemporary amenities and a cosy stay experience. Scheduled for opening in Q3 of 2024-25, ibis Styles Mysuru will offer 130 rooms, each with a unique character. The Food & Beverage offerings at the property will be designed to cater to diverse tastes, featuring an all-day dining restaurant, a specialty rooftop restaurant and a relaxing lounge bar. Additionally, the hotel will offer a comprehensive range of amenities, including a 450sqm banquet space, a well-equipped fitness centre and a relaxing swimming pool.

Mahindra & Mahindra announces price hike for passenger, commercial vehicles in 2024

Mahindra & Mahindra on Wednesday announced its decision to raise prices for both passenger and commercial vehicle models, effective from January 2024. This strategic move comes in response to the mounting challenges posed by inflation and the surge in commodity prices impacting the automotive sector. The company, acknowledging the economic strain, has diligently attempted to absorb a substantial portion of the escalated costs. Nevertheless, in order to maintain financial viability and sustain operations, Mahindra & Mahindra will pass on a proportion of the increased expenses to consumers.

Maruti Suzuki's first EV will be a top-end SUV with 550 km range, launching next year

Maruti Suzuki on Wednesday announced that its upcoming electric SUV will be manufactured in Gujarat, and a new plant will be added to the company's existing manufacturing facility in Hansalpur, nearly 90 km from here. Suzuki Motor Gujarat Private Ltd (SMG), which runs the car manufacturing plant at Hansalpur, is a wholly-owned subsidiary of Maruti Suzuki and commenced operation in February 2017. It will be a high-specification SUV having 550 km range (on a single charge) and a 60-kilowatt-hour battery. The upcoming EV SUV, to be produced at the SMG plant, will be exported too

Adani Group to invest USD 75 bn to scale up AGEL's RE portfolio to 45 GW: Gautam Adani

Adani Group has plans to invest USD 75 billion on energy transition initiatives by 2030, its chairman Gautam Adani said. The investments will boost the group's vision to have 45 gigawatt of renewable energy capacity by 2030, Adani said in a statement. The investments will be executed through Adani Green Energy Limited (AGEL).

Adani closing in to buy Shapoorji Pallonji Group's Gopalpur Ports in Orissa

Adani Ports and Special Economic Zone, India's biggest maritime company by market capitalisation, is in advanced talks to acquire Shapoorji Pallonji Group's (SP) Gopalpur Ports in Odisha for up to Rs 1,100-1,200 crore in equity value as part of a neatly woven string-of-pearls strategy that involves owning considerable facilities along both the eastern and western water margins.

If successful, this will be Adani Port's sixth acquisition of a multi-purpose facility on the eastern coast, where it already has approximately 247 million tonnes (MT) of capacity. The due diligence process is currently on, people aware of the talks told ET.



Coya Therapeutics, Inc. and Dr. Reddy's Laboratories entered into an Exclusive Collaboration for Development and Commercialization of COYA 302, an investigational combination therapy for treatment of Amyotrophic Lateral Sclerosis (ALS)

Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. and Coya Therapeutics, Inc. announced that they have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Under the terms of the Agreement, Coya has granted Dr. Reddy's an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the United States, Canada, the European Union and the United Kingdom for ALS. This Agreement is in addition to the in-licensing agreement with Dr. Reddy's signed in early 2023. Coya retains the right to commercialize COYA 302 for patients with amyotrophic lateral sclerosis (ALS) in Japan, Mexico, and each country in South America. Coya will have responsibility for the clinical development of COYA 302 and for seeking regulatory approval for COYA 302 for patients with ALS in the United States. Dr. Reddy's will make US\$ 7.5 million upfront payment to Coya. Upon the first FDA acceptance of an investigational new drug (IND) application for COYA 302 for the treatment of ALS, Dr. Reddy's will pay Coya an additional US\$ 4.2 million. Upon dosing of the first patient in the first Phase 2 trial of COYA 302 for the treatment of ALS in the United States, Dr. Reddy's will pay Coya an additional US\$ 4.2 million. Coya anticipates that the IND filing will be made in the first half of 2024. The Agreement also includes development and regulatory milestones up to US\$ 40 million should all such development and regulatory milestones be achieved. Additionally, Coya is eligible to receive sales-based milestone payments of up to US\$ 677.25 million linked to tiers of cumulative net sales being achieved over several years (over the term of the agreement subject to product commercial exclusivity). In addition, Dr. Reddy's will pay Coya royalties based on percentage net sales of COYA 302 ranging from low to middle teens. Coya is not a related party to Dr. Reddy's or its promoters/promoter group.



Important news/developments to influence markets

US Private Employment Below Forecasts

Private businesses in the US hired 103K workers in November 2023, below a downwardly revised 106K in October and expectations of 130K.

US Imports Hit 8-Month High

Imports into the United States grew by \$0.5 billion from the previous month to \$323.0 billion in October 2023, marking the highest level since February, primarily driven by a \$0.3 billion rise in goods purchases.

US Trade Gap Widens Slightly in October

The US trade gap widened slightly to \$64.3 billion in October 2023, the highest in three months, compared to a downwardly revised \$61.2 billion in September and forecasts of \$64.2 billion. It reflects an increase in the goods deficit of \$3.5 billion to \$89.8 billion and an increase in the services surplus of \$0.4 billion to \$25.5 billion.



Index	CMP	View	R1	R2	S1	S2
Nifty Dec Fut	21040	Bullish	21099	21159	20961	20881
BankNifty Dec Fut	46902	Bullish	47231	47561	46709	46515

Nifty – 60 min Timeframe chart



Nifty – Daily Timeframe chart



Daily Technical View on Nifty

- Nifty continued to its upward journey by rising for seventh consecutive session.
- Nifty registered a fresh all time high at 20961.
- Nifty has formed “Hanging Man” candlestick pattern on the daily chart. Bearish implication of this patterns will be validated only below low of the candle, placed at 20852.
- At present benchmark indices like Nifty, BankNifty, FinNifty, Nifty500, Nifty100, Nifty200, Midcap100 and Smallcap 100 are placed at their all-time highs.
- Nifty has been hitting fresh all-time highs for last 4 trading sessions and has reached in to uncharted territory.
- Immediate Support for the Nifty has now shifted up at 20852 odd levels.
- Next resistance for the Nifty is seen at 21193, which happens to be 61.8% Fibonacci extension level of the swing seen from 16828(March 2023 Bottom) to 20222(Sep 2023 Top) and from 20222 to 18837(Oct 2023 Bottom).



OPEN SHORT-TERM TRADING CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	CMP	SL	TARGET	UPSIDE %	VALID TILL
1	5-DEC-23	BUY	BANK NIFTY DEC FUT	47103-46900	46,900.15	46,800.0	47,550.0	1.4	8-DEC-23
2	6-DEC-23	BUY	NIFTY 07TH DEC 20900 CALL OPTION	56.4	85.00	37.0	90.0	5.9	11-DEC-23
3	4-DEC-23	BUY	RAMCO DEC FUT	1029.35-1011	1,025.80	996.0	1,085.0	5.8	18-DEC-23
4	30-NOV-23	BUY	INDIABULLS REAL ESTATE	82.80-81	81.55	79.0	89.0	9.1	14-DEC-23
5	1-DEC-23	BUY	BBTC	1404.45-1364	1,377.35	1,335.0	1,490.0	8.2	15-DEC-23
6	1-DEC-23	BUY	LINDE INDIA	5943.45-5760	5,881.75	5,645.0	6,295.0	7.0	15-DEC-23
7	1-DEC-23	BUY	BALMERLAWRIE	161.20-156	163.60	153.0	173.0	5.7	15-DEC-23
8	4-DEC-23	BUY	CARE RATING	937.95-915	946.60	893.0	1,012.0	6.9	18-DEC-23
9	4-DEC-23	BUY	GREAVES COTTON	138.50-133.80	136.75	131.9	146.0	6.8	18-DEC-23
10	5-DEC-23	BUY	SPARC	276.75-269	279.60	264.0	296.0	5.9	19-DEC-23
11	5-DEC-23	BUY	WELCORP	556.75-540	554.90	528.0	588.0	6.0	19-DEC-23
12	6-DEC-23	BUY	UFLEX	465-458	469.65	454.0	500.0	6.5	20-DEC-23
13	6-DEC-23	BUY	CHALET	588.55-569	589.60	563.0	621.0	5.3	20-DEC-23

OPEN E-MARGIN POSITIONAL CALLS

NO.	RECO DT.	RECO	COMPANY NAME	ENTRY	CMP	SL	TARGET 1	TARGET 2	UPSIDE %	VALID TILL
1	13-NOV-23	BUY	NCC	156-162.65	170.2	152.0	174.0	184.0	8	13-FEB-24
2	13-NOV-23	BUY	FORTIS	340-369	386.0	328.0	413.0	440.0	14	13-JAN-24
3	16-NOV-23	BUY	POLICY BAZAR*	753-784.90	843.7	785.0	845.0	910.0	8	16-JAN-24
4	16-NOV-23	BUY	DREAMFOLKS	530-550.90	544.9	505.0	597.0	650.0	19	16-FEB-24
5	17-NOV-23	BUY	RVNL	156-164.35	170.9	152.0	177.0	194.0	14	17-FEB-24
6	17-NOV-23	BUY	IRFC	72-76.65	75.8	69.5	85.0	89.0	17	17-JAN-24
7	21-NOV-23	BUY	BASF	2943-3066	3006.1	2882.0	3280.0	3525.0	17	21-FEB-24
8	21-NOV-23	BUY	EPL LTD	190-200.50	197.7	184.0	218.0	235.0	19	21-FEB-24
9	22-NOV-23	BUY	GLAND PHARMA*	1650- 1704.35	1767.9	1704.0	1810.0	1890.0	7	22-JAN-24
10	24-NOV-23	BUY	SUBROS	413-429.10	442.1	404.0	460.0	494.0	12	24-FEB-24
11	4-DEC-23	BUY	HUDCO	84-86.50	86.8	81.0	92.7	100.0	15	4-MAR-24
12	4-DEC-23	BUY	LIFE INSURANCE CORP*	670-690.80	746.0	691.0	742.0	800.0	7	4-FEB-24
13	4-DEC-23	BUY	CENTRAL BANK	46.50-44	47.9	42.7	50.0	55.0	15	4-MAR-24
14	6-DEC-23	BUY	SHYAM METALICS	496.85-471	514.5	456.0	542.0	575.0	12	6-MAR-24
15	6-DEC-23	BUY	ITC	450-459.65	463.3	433.0	491.8	520.0	12	6-FEB-24
16	6-DEC-23	BUY	ROSSARI BIOTECH	753-791.05	831.1	722.0	890.0	925.0	11	6-MAR-24

*= 1st Target Achieved



Disclaimer:

This report has been prepared by HDFC Securities Ltd and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. HSL is not obliged to update this report for such changes. HSL has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject HSL or its affiliates to any registration or licensing requirement within such jurisdiction.

If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations, which could have an adverse effect on their value or price, or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies effectively assume currency risk. It should not be considered to be taken as an offer to sell or a solicitation to buy any security.

This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with HSL. HSL may from time to time solicit from, or perform broking, or other services for, any company mentioned in this mail and/or its attachments.

HSL and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

HSL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

HSL and other group companies, its directors, associates, employees may have various positions in any of the stocks, securities and financial instruments dealt in the report, or may make sell or purchase or other deals in these securities from time to time or may deal in other securities of the companies / organizations described in this report. As regards the associates of HSL please refer the website.

HSL or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

HSL or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction in the normal course of business.

HSL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither HSL nor Research Analysts have any material conflict of interest at the time of publication of this report. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. HSL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Research entity has not been engaged in market making activity for the subject company. Research analyst has not served as an officer, director or employee of the subject company. We have not received any compensation/benefits from the subject company or third party in connection with the Research Report.

HDFC securities Limited, I Think Techno Campus, Building - B, "Alpha", Office Floor 8, Near Kanjurmarg Station, Opp. Crompton Greaves, Kanjurmarg (East), Mumbai 400 042 Phone: (022) 3075 3400 Fax: (022) 2496 5066

Compliance Officer: Murli V Karkera Email: complianceofficer@hdfcsec.com Phone: (022) 3045 3600

For grievance redressal contact Customer Care Team Email: customercare@hdfcsec.com Phone: (022) 3901 9400

HDFC Securities Limited, SEBI Reg. No.: NSE, BSE, MSEI, MCX: INZ000186937; AMFI Reg. No. ARN: 13549; PFRDA Reg. No. POP: 11092018; IRDA Corporate Agent License No.: CA0062; SEBI Research Analyst Reg. No.: INH000002475; SEBI Investment Adviser Reg. No.: INA000011538; CIN - U67120MH2000PLC152193

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Mutual Funds Investments are subject to market risk. Please read the offer and scheme related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#HDFCsecMythBusters



**Scan the code to
download our mobile app now!**

Global Investing, Basket Investing are not a Exchange traded product and all disputes related to the distribution activity of Global Investing and Basket Investing will not have access to Exchange investor redressal forum or Arbitration mechanism. Involvement of HDFC securities is restricted to Referral only. HDFC securities does not offer this product directly to customers <https://www.hdfcsec.com/globalinvesting>. Account would be opened after all procedure relating to IPV and client due diligence is completed. Investment in securities market are subject to market risks, read all the related documents carefully before investing. SEBI registration & disclaimers: <https://www.hdfcsec.com/article/disclaimer-1795>.

The information is only for consumption by the client and such material should not be redistributed.